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A B S T R A C T
Purpose
Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma. There is a need
for multicenter trials involving defined patient populations using rigorous assessment criteria. We
have investigated pegylated liposomal doxorubicin (PLD) in a clearly defined patient population
with advanced MF.
Patients and Methods
Eligible patients had stage IIB, IVA, or IVB MF, refractory or recurrent after at least two previous
systemic therapies. Patients were registered to receive a maximum of six cycles of PLD 20 mg/m2
on days 1 and 15, every 28 days (one cycle). The primary end point was response rate (RR).
Results
Nine centers recruited 49 eligible patients. The median number of chemotherapy cycles received
was five. There were no grade 3 to 4 hematologic toxicities. Grade 3 or 4 nonhematologic/
nonbiochemical toxicities included cardiac symptom (2%), allergy/hypersensitivity (2%), constitu-
tional symptom (4%), hand and foot reaction (2%), other dermatologic toxicity (6%), other GI
toxicity (4%), infection (4%), pulmonary embolism (2%), and cardiac ischemia (2%). Of 49
patients, 20 (40.8%) were responders (complete clinical response [CCR] or partial response [PR]
as overall response): three (6.1%) experienced CCRs, and 17 (34.7%) experienced PRs. A 50% or
greater reduction of cutaneous manifestations was observed in 26 (60.5%) of 43 assessable
patients. Two early deaths were reported, resulting from related cardiovascular toxicity and
disease progression. The lower limit of the one-sided 90% CI for RR was 31.2%. Median time to
progression and median duration of response were 7.4 and 6 months, respectively.
Conclusion
PLD has an acceptable safety profile in patients with advanced MF. The efficacy of PLD
seems promising.
J Clin Oncol 30:4091-4097. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Primary cutaneous T-cell lymphomas (CTCLs)
constitute a broad spectrum of disease entities with
different clinicopathologic, phenotypic, andmolec-
ular features, characterizedbyaclonal accumulation
of T cells in the skin.1 The incidence of CTCL has
increased during the last decades, with a recent esti-
mated incidenceof6.4newcasespermillionperson-
years.2 The most common subtype is mycosis
fungoides (MF), accounting for more than 80% of
CTCL cases.3,4 MF is clinically characterized by
long-standing scaly patch lesions usually involving
the limb girdle areas and, in a minority, by a slow,
progressive evolution over years or even decades
from patches to more infiltrated plaques, tumors,
erythroderma, and/or visceral involvement.4
The therapeutic strategy depends on the stage
of disease.5,6 Indeed, the overall survival (OS) of
patients with limited patch- or plaque-stage disease
is similar to that of an age- and sex-matched control
population, whereas 5-year OS drops down to
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approximately 45% in tumor-stageMFand to approximately 20%for
patients with nodal involvement.6-8 Accordingly, treatment op-
tions for early-stage disease involve skin-directed therapies such as
phototherapy, topical nitrogen mustard, or radiotherapy. For pa-
tients with intermediate- or early-stage disease with resistance to
skin-directed therapies, biologics such as interferon alfa and the
rexinoid bexarotene are used.9,10 However, the treatment of
advanced-stage MF is still a challenge, despite new biologic and
targeted therapies and particularly in view of the short duration of
response (DOR).11 Systemic polychemotherapy is widely used.10
Although response rates (RRs) are high in uncontrolledmonocen-
tric studies (from 55%up to 81%),9 remissions are invariably short
lived. The clinical activity of multiagent chemotherapy in terms of
both RR and remission duration has not been shown to be superior
to single-agent chemotherapy; moreover, multiagent chemo-
therapy is accompanied by an increased risk of myelosuppression
and infection.9,10
Pegylated liposomal doxorubicin (PLD) is a new formulation of
doxorubicin in which the drug is encapsulated in liposomes and
stabilized by the attachment of polyethylene glycol (ie, pegylation) to
the liposomal surface, resulting in increased half-life and improved
accumulation in tumor tissues.12-14 Its toxicity profile is characterized
by dose-limitingmucosal and cutaneous adverse effects, in particular
palmo-plantar erythrodysesthesia syndrome, reported inup to20%of
treated patients.15,16
The use of PLD in CTCL has been reported previously, but
interpretation of these reports is hampered by the heterogeneity of
diagnosis, stage, anddosage appliedand/orby the retrospectivenature
of the studies aswell as the lack of rigorous disease assessment criteria.
There is an urgent unmetmedical need for an effective approach that
avoidsmyelosuppression in patients with advanced disease. Thus, the
European Organisation for Research and Treatment of Cancer
(EORTC) Cutaneous Lymphoma Task Force initiated this trial.
PATIENTS AND METHODS
General Objective and Outline
This was a single-arm phase II study of PLD (Caelyx; Janssen Pharma-
ceuticals, Beerse, Belgium) in patients with stage IIA, IVA, or IVB advanced
MF. After completion of screening investigations, eligible patients were regis-
tered to receivePLDasmonotherapy intravenouslyduring1-hour infusions at
a dose of 20 mg/m2 on days 1 and 15, every 28 days (one cycle). A minimum
washout period of 2 weeks, during which patients were not allowed to receive
any therapy, was required before starting treatment. Treatment started within
5 days of registration. Patients were treated until they received amaximum of
six cycles of therapy, reached amaximum cumulative dose of antracyclines of
400 mg/m2 (including antracyclines from pretreatment), experienced pro-
gressive disease or excessive toxicity, or refused further treatment, or until a
clinical decision was made to start a new anticancer therapy. Disease was
assessed every two cycles until documented progression, and adverse effects of
treatment were assessed for each cycle of therapy. Evaluation of the extent of
cutaneous involvementwith thediseasewasperformedby assessing the tumor
burden index (TBI) based on the modified severity-weighted assessment
tool17; extracutaneous disease assessment was performed by using chest x-ray
and abdominal and lymph node ultrasound.
Theprotocolwas approvedby the ethics committeeof eachparticipating
institution, and written informed consent was obtained from every patient. A
general outline and CONSORT diagram are provided in Figure 1.
Patient Selection Criteria
Patients eligibility criteriawere as follows: histopathologically confirmed
diagnosis of stage IIB, IVA1/2, or IVBMF18; no CNS involvement or erythro-
derma (T4); refractory or recurrent disease after two or more previous thera-
pies; no systemic treatment with steroids at the time of study entry; and age
 18 years. Prior systemic chemotherapy was allowed if all of the following
conditions weremet: anthracycline cumulative dose 200mg/m2, no allergy
to anthracyclines, and low-dosemethotrexate (weeklydose30mg).Patients
requiring systemic treatment with steroids for any reason at the time of study
entry were excluded. Topical steroid therapy for itch control was allowed, if
usedbefore study entry. In addition, patients had tohave: ECOGperformance
status (PS) of 0 to 2; no other prior or concurrent primary malignant tumor
(except adequately treated in situ carcinomaof the cervixuteri or squamousor
basal cell skin carcinoma); no active infection requiring specific therapy (eg,
antibiotics, anti-HIV therapy); left ventricular ejection fractionwithin normal
limits of each institution, measured by echocardiography or by radionuclide
angiocardiography; adequate hematologic function (hemoglobin  10g/dL,
WBC  2  109/L, platelets  75,000/L, neutrophiles  1.5  109/L);
adequate renal and liver functions (serum creatinine and serum bilirubin
 1.5 the upper limit of normal for the institution, AST/ALT 2.5 the
upper limit of normal for the institution). An appropriate method of contra-
ception was necessary.
Written informed consent was obtained before patient inclusion, ac-
cording to International Conference on Harmonisation/European Union
Good Clinical Practice and national and local regulations. The protocol, pa-
tient information sheets, and consent forms were translated and approved by
all national and regional ethics and research boards in the United Kingdom,
Germany, Italy, Switzerland, Austria, and Israel.
End Points and Disease Assessment
The primary end point was overall RR, defined as the proportion of
patients responding (complete clinical response [CCR] or partial response
[PR;  50% reduction of skin manifestations]) to treatment as assessed by
local investigators. Disease assessment for the primary end point was con-
ducted at baseline, once every 8weeks during treatment, at the endof protocol
treatment, and once every 12 weeks after the end of protocol treatment until
disease progression. Disease assessment consisted of cutaneous disease evalu-
ation using an internationally accepted skin scoring system17,19 for cutaneous
involvement (TBI) and the documentation of extracutaneous lesions, as sug-
gestedby the consensus response criteria publishedbyOlsen et al.20 Secondary
end points were toxicity of treatment scored according to the Common Ter-
minology Criteria for Adverse Events version 2.0, time to progression (TTP),
and duration of response (DOR).
Sample Size and Statistical Method
To determine the success of treatment, a one-step Fleming design was
used, with  set at 0.10 and  at 0.05. P0 was set at 25% and defined as the
largest RR that if true implied that the arm did not warrant further investiga-
tion.P1was set at 45%anddefinedas the lowestRR that if true implied that the
armdidwarrant further investigation. Under this hypothesis, the total sample
size was calculated to be 48 eligible patients who started treatment. If 15
responses of 48were obtained, the arm should be further investigated. Ifmore
than 48 eligible patients started treatment, the drug should be further investi-
gated when the lower bound of the 90% one-sided CI for RRwas 25% (the
RRused in thenull hypothesis). All statistical analyses, tables, and listingswere
performed using SAS version 9.1 (SAS Institute, Cary, NC).
RESULTS
The studywas opened inNovember 2003 and closed in July 2009. The
CONSORT diagram is depicted in Figure 1. In total, 49 patients were
registered from six countries and nine centers. All registered patients
were eligible and started treatment. The median follow-up time was
10.6 months.
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Major demographics and patient characteristics are listed in
Table 1.Most patients had a PS of 0 or 1 (96%), had refractory disease
(71%),weremen (67%), andwere between the ages of 56 and75 years
(63%). Prior therapies included combination therapywith orwithout
chemotherapy (22% and 41%, respectively), chemotherapy alone,
and topical treatment with or without chemotherapy (14% and
12%, respectively).
Thenumber of cycles of treatment is listed inAppendixTableA1
(online only). The median number of cycles was five (range, one to
six), and themediandurationof chemotherapywas20weeks (range, 4
to 20 weeks). Amajority of patients (88%) had relative dose-intensity
of 110%. Dose modifications and dose delays were reported in eight
(16.3%) and 19 (38.8%) patients, respectively; the main reasons for
dose modification or delay were nonhematologic toxicities (48%)
followed by patient personal reasons (36%), and hematologic toxici-
ties (9%); the reason was unknown in 7%. Single-cycle dose delays
were noted in only 24.5% of patients. Dose interruptions defined as
dose skippedordefinitely stoppedduring thecyclewere reported in17
patients (34.7%). Reasons for dose interruptions were nonhemato-
logic toxicities (59%) followed by patient personal reasons (17%) and
progression or other medical reasons (12% for each). Of 26 patients
with a PS of 1 at baseline, 31% experienced improvement in their
condition to a PS of 0, and 23% experienced deterioration of their
condition to a PS of 2. Prophylactic antiemetics were administered
88% of patients; 84% had a PS of 0 to 1 during treatment. No patient
received granulocyte-macrophage colony-stimulating factor or ther-
apeutic antiemetics.
Toxicity is summarized in Appendix Table A2 (online only).
There were no grade 3 to 4 hematologic toxicities; only grade 2 neu-
tropenia (n  2), leukopenia (n  2), and anemia (n  2) were
observed during treatment. Grade 3 to 4 nonhematologic or nonbio-
chemical toxicities included cardiac symptom (n 1), allergy/hyper-
sensitivity (n  1), constitutional symptom (n  2), hand and foot
reaction (n 1), other dermatologic toxicity (n 3),GI toxicity (n
2), and infection (n 2).Onepatient experienced grade 4pulmonary
embolism, one experienced grade 4 cardiac ischemia, and two experi-
enced grade 3 middle-ear inflammation. Early deaths (death before
the first tumor evaluation [ie, within 8 weeks of entering the study])
were reported in two patients; one was the result of related cardiovas-
cular infarction, and the other resulted from disease progression.
RR is summarized in Table 2. Of 49 patients who were eligible
and started treatment, 20 (40.8%) were responders: three (6.1%)
experienced CCRs, and 17 (34.7%) experienced PRs. The lower limit
of the one-sided 95% CI for RR was 31.2%. There was only a minor
difference in the efficacy (RR) of therapy in patients with high versus
low cutaneous tumor burden (32% v 50%; 95% CI,13% to 49%).
Of 36 patients who were chemotherapy naive at registration, 11
(35.5%) were responders, compared with nine responders (50%) of
18 patients who received prior chemotherapy (95% CI, 18% to
47%). Response to treatment in cutaneous disease is shown in Figure
Registration
   Histopathologically confirmed MF stage IIB,
      IVA, and IVB
   No CNS involvement and no erythroderma (T4)
   Two or more previous therapies
   No systemic corticosteroids at entry; topical 
      corticosteroid therapy for itch control was 
      allowed if used before study entry
PLD monotherapy (maximum of 6 cycles)
   PLD intravenous monotherapy 20 mg/m2 
      on day 1 and 15, every 28 days
   All patients started monotherapy
   Median (range) of total number of cycles
      administered: 5 (1-6)
Analyzed
   Analysis was based on per-protocol population, 
      eligible patients who started treatment
(n = 49)
Response evaluation every 8 weeks
   Cutaneous disease (assessed using TBI/mSWAT)
   Extracutaneous disease (assessed using complete 
      examination, chest X-ray, abdominal and lymph 
      node ultrasound)
(n = 49)
All patients were eligible (n = 49)
Protocol violation
   Undertreated
   Overtreated
(n = 4)
(n = 2)
(n = 2)
Fig 1. General outline and CONSORT
diagram of the EORTC (European Organi-
sation for Research and Treatment of Can-
cer) 21012 study. MF, mycosis fungoides;
mSWAT, modified severity-weighted as-
sessment; PLD, pegylated liposomal doxo-
rubicin; TBI, tumor burden index.
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2. The waterfall plot depicts the percentage change in patient TBI
during treatment relative to baseline TBI. Patients with lymph node
and/or visceral involvement (stage IVA/B) had a lower RR than pa-
tients with exclusive skin manifestations (stage IIB; 22% v 52%; 95%
CI, 1% to 60%), as summarized in Appendix Table A3 (online
only). In six patients, the response in extracutaneous sites was lower
than that in the skin,whereas inmost patients, the response in the skin
was lower than that in extracutaneous sites.
Secondary end points TTP (defined as the interval of time be-
tween the date of registration and the date of first documentation of
disease progression) and DOR (measured from the time that mea-
surement criteria were met for CCR/PR [whichever was first re-
corded] until the first date that recurrent or progressive disease was
objectively documented) are shown in Figure 3 and Appendix Figure
A1 (online only), respectively. For both TTP and DOR, event was
defined as disease progression. Patients who died without progressive
disease were censored at the date of death. Patients alive without
progressive disease were censored at the last date they were known to
be alive. In DOR analysis, only responders (patients with CCR or PR)
were included.
Of 49 patients, 35 progressions were observed. Themedian TTP
was 7.4months (95%CI, 4.5 to 8.6months).Of 20 responders (CCR/
PR), 14 experienced progression. The median DOR was 6 months
(95% CI, 5.0 to 10.4 months). At the closure of the study, 14 deaths
Table 1. Patient Baseline Demographics and Clinical Characteristics (N  49)
Characteristic
Patients
No. %
Age category, years
26-35 2 4.1
36-45 1 2.0
46-55 7 14.3
56-65 16 32.7
66-75 15 30.6
 75 8 16.3
ECOG PS
0 21 42.9
1 26 53.1
2 2 4.1
Skin patches/plaques
No 1 2.0
Yes, % BSA
 10 8 16.3
 10 40 81.6
Skin tumors
No 10 20.4
Yes 39 79.6
Clinical lymph node
No 24 49.0
Yes 25 51.0
Histologic lymph node
No 34 69.4
Yes 15 30.6
Visceral disease
No 44 89.8
Yes 5 10.2
Refractory/recurrent disease
Refractory 35 71.4
Recurrent 14 28.6
Sex
Male 33 67.3
Female 16 32.7
Prior treatment
Immunotherapy 3 6.1
Radiotherapy 2 4.1
Chemotherapy 7 14.3
Topical treatment 6 12.2
Combination treatment
With chemotherapy 11 22.4
Without chemotherapy 20 40.8
Duration from last treatment to trial entry/registration, days
Median 44.0
Range 14.0-9,599.0
Abbreviations: BSA, body surface area; ECOG PS, Eastern Cooperative
Oncology Group performance status.
Table 2. Best Response Overall and by Baseline TBI
Best Overall Response
to Treatment
Overall
(N  49)
Baseline TBI
Low
(n  24)
High
(n  25)
No. % No. % No. %
CCR 3 6.1 3 12.5 0 0.0
PR 17 34.7 9 37.5 8 32.0
SD 14 28.6 7 29.2 7 28.0
PD 5 10.2 1 4.2 4 16.0
Early death
Toxicity 1 2.0 0 0.0 1 4.0
Other 1 2.0 0 0.0 1 4.0
Not assessable 8 16.3 4 16.7 4 16.0
NOTE. Best overall response (CCR/PR) rate is 40.8%. Exact one-sided 90%
CI is 31.2% to 100%.
Abbreviations: CCR, complete clinical response; PD, progressive disease;
PR, partial response; SD, stable disease; TBI, tumor burden index.
Median of baseline TBI 60 was used as a cutoff point to separate low and
high TBI.
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Fig 2. Waterfall plot of the percentage change in tumor burden index (TBI). Star
symbols represent patients with nonevaluable TBI.
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had been observed. Causes of death were disease progression (n 7),
cardiovascular infarction (n  2), second primary tumor (n  1),
acute perforated gastric ulcer (n 1), diabetes (n 1), and infection
(n 2).
DISCUSSION
This trial using PLD in advancedMF is of special interest for the field
ofCTCL, because it investigates for thefirst time toour knowledge the
outcome of PLD therapy in a clearly defined population of patients
with MF urgently in need of cytotoxic therapy. This homogenous
population represents the difficult-to-treat elderly patients with MF
with disfiguring skin tumors and/or extracutaneous involvement.
Most patients had undergone several previous treatments. This is in
contrast tomanyother trials,whicharedifficult to interpretbecauseof
the heterogeneity of diagnosis and varying disease assessments and
end points.
The patient population was restricted to a stage of MF with
tumors and/or extranodal involvement. Eighty-eight percent of the
patients received at least 70% of the planned total dose. PS, age, and
pretreatment reflect a realistic population of patients with advanced
MF. As shown in Figure 2, with PLD, a substantial improvement in
cutaneous lymphomamanifestationswas achieved inmore than 80%
of patients. This was independent from the extracutaneous involve-
ment, which might be explained by a favorable accumulation of the
drug in the skin. Because resolution of the disfiguring cutaneous
manifestations is crucial to quality of life in this patient population,
these cutaneous remissions meet the clinical needs. Moreover, the
tolerability of PLD was excellent, without grade 3 to 4 hematologic
toxicities or septic complications in a patient population of advanced
age; these figures compare favorably with polychemotherapy-
associated adverse effects. The overall RRof 40.8% is lower than those
reported in other trials using PLD, which have includedmore hetero-
geneous populations with regard to stage and diagnosis (Table 3). A
reduction in cutaneousmanifestations of at least 50%was observed in
26 (60.5%)of 43 assessablepatients. Pretreatmentwith chemotherapy
andextentof skin involvementhadnonegative impactonresponse, in
contrast to extracutaneous involvement (stage IVA/B). As expected,
the CCR was low (6%), and the median PFS after discontinuation
of therapy calculated frommature datawas 7.43months, highlighting
the limitations of chemotherapy and the need for long-term well-
tolerated maintenance treatment.26 Cycling between cytoreductive
andmaintenance therapies will be the favored therapeutic strategy in
the future; it is currently being studied in the ongoing EORTC
CTCL protocol.
This is a key report for future therapeutic developments in ad-
vanced CTCL. For the first time to our knowledge, RR and DOR in a
well-defined population of patients with the most common type of
CTCL were determined. There has been one large randomized trial
comparing aggressive chemotherapy combined with total skin irradi-
ation with a stepwise adapted mild therapy.27 However, the major
drawback of this trial was the lack of a generally accepted classification
at trial initiation, which prevented clear insight into the patient popu-
lation treated. This drawback applies tomany clinical trials performed
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Table 3. Summary of Various Prior Studies in CTCL Relative to the Current Study
Variable Wollina et al21 (2003)
Di Lorenzo et al22
(2005) Pulini et al23 (2007) Quereux et al24 (2008) EORTC 2101225
No. of Patients 34 10 19 25 49
Design Retrospective multicenter Retrospective single
center
Prospective multicenter Prospective multicenter Prospective multicenter
controlled
CTCL subtypes and stages 31 MF IB to IVA (n  31);
SS (n  1); PTCL-U
(n  2); CD30 ALCL
(n  1)
MF IVB MF IB to IVB; SS;
PTCL-U
MF IIB to IVB (n  15);
SS (n  10)
MF IIB (n  31); MF
IVA/B (n  18)
Schedule 20-40 mg/m2 every 2-4
weeks
20 mg/m2 every 4
weeks
20 mg/m2 every 4
weeks
40 mg/m2 every 4
weeks
20 mg/m2 every 2
weeks
ORR, % 88.2 30 84.2 56 40.8
CR, % 44.1 0 42.1 20 6.1
Median PFS, months NA NA 19 5 6.2
Median OS, months 17.8 NA 34 43.7 NR
Toxicity (grade 3 to 4), % 17.6 10 11 40 20
Abbreviations: ALCL, anaplastic large-cell lymphoma; CR, complete response; CTCL, cutaneous T-cell lymphoma; EORTC, European Organisation for Research and
Treatment of Cancer; MF, mycosis fungoides; NA, not available; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival;
PTCL-U, peripheral T-cell lymphoma unspecified; SS, Sezary syndrome.
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in the 1980s (summarized by Bunn et al17). There have been large
registration trials sponsored by the pharmaceutical industries aiming
to demonstrate the potency of bexarotene,28 vorinostat and panobi-
nostat (Duvic et al, submitted for publication),29,30 and IL-
2diphtitox.31,32 These trials included patients with CTCL of various
subtypes and stages to improve recruitment andprovide the statistical
power to detect beneficial effects if they exist.
Trials investigating the use of PLD in CTCL published earlier
included not onlyMF but Se´zary syndrome (SS), unspecified periph-
eral T-cell lymphomas, and CD30 anaplastic large-cell lymphomas
aswell. Somewereretrospectivepatientcasecollections,which implies
a high risk for positive bias. Moreover, two of these studies21,23 in-
cluded early-stageMF. These circumstancesmight explain the higher
RRs reported (88.2% and 84.2%, respectively) in comparison with
those reported in a French trial22 and in the trial byDi Lorenzo et al,24
who included only patients with MF with visceral involvement (56%
and 30%, respectively). With regard to drug schedule, the French
study anticipated theuseofhigherdosages (40mg/m2) for all patients,
whereas the other studies used lower drug doses; the different sched-
ules could explain the significantly higher toxicities (40%grade 3 to 4)
experienced in the French study.
The comparison of PLD clinical activity with respect to that of
standard mono- or polychemotherapy regimens is difficult. Gemcit-
abine is a widely used treatment option forMF; however, although its
activity is well documented, literature data are difficult to compare.
RRs rangedbetween 62%and75%according to different reports,33-35
but inclusion criteria for treatmentwere different; one study included
only untreated patients,33 whereas another also included those with
early-stageMF.34Moreover,with respect to thepresentEORTCstudy,
treated patients included those with erythrodermicMF, SS, and non-
MF/SS CTCLs. Regarding adverse effects, the original report byMar-
chi et al33 showed a favorable toxicity profile, whereas the French
group35 reported severe hematologic toxicities in 30% of patients,
serious infection complications in 26% of patients, and other serious
adverse events in 26%of patients, thus contradicting previous studies.
One single-institution study reported a 40%RRwith amedian remis-
sion duration of 5.7months in patients with CTCL treated with COP
(cyclophosphamide, vincristine, and prednisone) or CHOP (cyclo-
phosphamide, doxorubicin, vincristine, andprednisone).36Manyun-
controlled studies performed in the 1970s and 1980s indicated RRs of
70%orhigherwithCHOPchemotherapy.However, there is no infor-
mationon the stage or the precise diagnosis of the patientswithCTCL
treated,17 and the remission duration reported did not exceed 6
months in the majority of patient cases.
In summary, this trial has producedbenchmarkdata in a defined
population of patients with MF in need of cytotoxic therapy. The
efficacy is reasonable, but there is definitely a need for improvement.
The inclusion criteria will be used for many additional trials in the
CTCL field. The information on PFS after treatment discontinuation
provides the setting for new trials of maintenance therapy.
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